Agreed with the caveat that we need to know a lot more about not only the new formulation, but how insurance companies will handle it and how docs and patients may or may not try to subvert it with GV. Yes, I know less API so the new formulation costs less. But that costs less is to Amarin and not necessarily what patients would pay. Again I could be all wet with this type of speculation but it just shows that we know so little about it and its ramifications in the marketplace.
Market Data 
Markets 
AI
